Abstracts Archive - Page 620 of 2607 - ACR Meeting Abstracts

Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu¹, Allison Perry², Nicole Zimmerman³, Helen Varker⁴, Rich Bizier⁴, Liisa Palmer⁴, Christine Dube⁵ and Gary Bryant⁶, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³IBM Watson Health, Chagrin Falls, OH, ⁴Merative, Cambridge, MA, ⁵AstraZeneca, Torrington, CT, ⁶AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
Abstract Number: 2060 • ACR Convergence 2022
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Gul Karakoc, Ge Liu, Jorge Gamboa, Cecilia Chung, Jonathan Mosley, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: SLE disproportionately affects individuals of African (AA) compared to European ancestry (EA). In addition to a higher incidence, the disease is more severe in…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2070 • ACR Convergence 2022
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
Sarah Dyball¹, John Reynolds², Hector Chinoy³, Ariane Herrick¹, Sahena Haque⁴, Ellen Bruce⁵, Sophia Naz⁶, Ben Parker⁷ and Ian N. Bruce⁸, ¹The University of Manchester, Manchester, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³The University of Manchester, Sale, United Kingdom, ⁴Manchester Foundation Trust, Manchester, United Kingdom, ⁵Kellgren Centre for Rheumatology, Manchester, United Kingdom, ⁶Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ⁷Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁸Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…
Abstract Number: 2069 • ACR Convergence 2022
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Aarabi Thayaparan¹, Patricia Katz², Mitra Moazzami³, Dennisse Bonilla¹, Lisa Engel⁴, Jiandong Su¹, Pooneh Akhavan⁵, Sherief Marzouk⁶, Nathalie Rozenbojm⁷, Nicole Anderson¹, Oshrat Tayer-Shifman⁸, Dorcas Beaton⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²UCSF, San Rafael, CA, ³George Washington University, Washington, DC, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada, ⁸Meir Medical Center, Kfar Saba, Israel, ⁹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Clinicians should include Patient-Reported Outcome (PRO) measures in the assessment of lupus patients, as they are crucial in providing patient-centred care. The Patient Reported…
Abstract Number: 2066 • ACR Convergence 2022
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
Daniela Marengo-Rodriguez¹, Astrid Hernandez-De La Torre¹, Maria Jose Chavez-Barajas¹, André Fortanell-Meza², Ana Barrera-Vargas², Diego San Agustin-Morales² and Javier Merayo-Chalico³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Patients with SLE present with greater sexual dysfunction (SxD) than patients with other chronic diseases [1]. These patients tend to be younger compared to…
Abstract Number: 2067 • ACR Convergence 2022
Predictors of Organ Damage Accrual by Domains
Rangi Kandane-Rathnayake¹, Ning Li¹, Vera Golder¹, Worawit Louthrenoo², Yi-Hsin Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao¹⁴, Zhouli Zhang¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Shereen Oon¹⁹, Sang-Cheol Bae²⁰, Fiona Goldblatt²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Duminda Basnayake²⁵, Nicole Tugnet²⁶, Sunil Kumar²⁷, Cherica Tee²⁸, Michael Tee²⁸, Yoshiya Tanaka²⁹, Chak Sing³⁰, Mandana Nikpour³¹, Alberta Hoi³² and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Chiang Mai University, Chiang Mai, Thailand, ³Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰People's Hospital, Peking University Health Science Center, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴The University of Melbourne, Melbourne, Australia, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹St Vincent's Hospital, Fitzroy, Australia, ²⁰Hanyang University Medical Center, Seoul, Republic of Korea, ²¹Flinders Medical Centre, Adelaide, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ²⁶Greenlane Clinical Centre, Auckland, New Zealand, ²⁷Middlemore Hospital, Auckland, New Zealand, ²⁸University of the Philippines, Quezon City, Philippines, ²⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash Health, Melbourne, Australia, ³³Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Prevention of organ damage is one of the main treatment goals in systemic lupus erythematosus (SLE).The SLICC/ACR Damage Index (SDI) is used to quantify…
Abstract Number: 2042 • ACR Convergence 2022
Sjögren’s Disease and Mitochondrial Function
Biji T Kurien¹, Pharaoh Gavin², Joshua Cavett¹, Valerie Lewis³, Ambre Chambers¹, Bhaskaran Shylesh⁴, Anjum Juvaria¹, Brittany Karfonta¹, Lida Radfar¹, Astrid Rasmussen⁴, Christopher Lessard⁴, Darise Farris⁴, Kathy Sivils⁵, Kristi A Koelsch⁴, Holly Van Remmen⁴ and R. Hal Scofield¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Washington, Seattle, WA, ³Veterans Affairs Medical Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Sjögren's disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 2015 • ACR Convergence 2022
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Naoki Iwamoto², Shoichi Fukui², Fumiko Shomura³, Koichiro Aratake³, Toshiyuki Aramaki⁴, Yukitaka Ueki⁴ and Atsushi Kawakami², ¹Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Ureshino, Japan, ²Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan, ⁴Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan

Background/Purpose: Tofacitinib and baricitinib are the first and second approved JAK inhibitors for rheumatoid arthritis (RA) patients. Although their clinical efficacy has been well established,…
Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Amit Saxena¹, Alexis Engel², Brittany Banbury¹, Ghadeer Hasan³, Nicola Fraser¹, Devyn Zaminski¹, Mala Masson⁴, Rebecca Haberman⁵, Jose Scher², Gary Ho⁶, Jammie Law³, Paula Rackoff¹, Chung-E Tseng⁵, H Michael Belmont¹, Robert Clancy¹, Jill Buyon⁷ and Peter Izmirly⁷, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone, New York, NY, ⁴NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
Abstract Number: 2078 • ACR Convergence 2022
Mesangial Lupus Nephritis: Long Term Outcomes
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Mesangial lupus nephritis (LN class II) is generally considered benign with minimal potential for developing advanced chronic kidney disease (CKD). However, a certain proportion…
Abstract Number: 2079 • ACR Convergence 2022
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
Wils Nielsen¹, Vibeke Strand², Lee S Simon³, Julian Thumboo⁴, Marta Mosca⁵, Martin Aringer⁶, Sindu Johnson⁷, Aaron Drucker⁷, Eric Morand⁸, Ian N. Bruce⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³SDG LLC, West Newton, MA, ⁴Singapore General Hospital, Bukit Merah, Singapore, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁶University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁷University of Toronto, Toronto, ON, Canada, ⁸Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The development of a Core Outcome domain Set (COS) can aid research communication and standardizing measurement tools of SLE. A COS captures SLE facets…
Abstract Number: 2080 • ACR Convergence 2022
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
Rashmi Dhital¹, Monica Guma², Brian Pedersen¹, Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³William Beaumont Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].